The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

SureCN8023     7-(4-amino-6-methyl-oxan-2- yl)oxy-6,9,11...

Synonyms: Neuro_000133, AC1L8OJG, 63521-85-7
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of NSC267469


High impact information on NSC267469


Analytical, diagnostic and therapeutic context of NSC267469


  1. Phase II trial of esorubicin (4' deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma. Braich, T.A., Salmon, S.E., Robertone, A., Alberts, D.S., Jones, S.E., Miller, T.P., Garewal, H.S. Investigational new drugs. (1986) [Pubmed]
  2. Phase II trial of 4' deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma. An Illinois Cancer Council study. Rose, C., Lad, T.E., Kilton, L.J., Schor, J., Rosen, S.T., Rossof, A.H., Blough, R.R., Johnson, C.M. Investigational new drugs. (1990) [Pubmed]
  3. Phase II study of deoxydoxorubicin in previously untreated metastatic breast cancer. Martino, S., Samal, B.A., Redman, B., Flaherty, L., Kraut, M., Simon, M., Valdivieso, M. Breast Cancer Res. Treat. (1990) [Pubmed]
  4. Phase II study of deoxydoxorubicin in patients with advanced liver cancer. Perry, D.J., Van Echo, D.A., Mick, R. Cancer treatment reports. (1987) [Pubmed]
  5. Cinchonine, a potent efflux inhibitor to circumvent anthracycline resistance in vivo. Genne, P., Dimanche-Boitrel, M.T., Mauvernay, R.Y., Gutierrez, G., Duchamp, O., Petit, J.M., Martin, F., Chauffert, B. Cancer Res. (1992) [Pubmed]
  6. Esorubicin (deoxydoxorubicin) has low grade activity in malignant melanoma. Results of an Eastern Cooperative Oncology Group study (EST 2685). Hochster, H., Hunt, M., Green, M., Parkinson, D., Smith, T. Investigational new drugs. (1990) [Pubmed]
  7. Doxorubicin and C-13 deoxydoxorubicin effects on ryanodine receptor gene expression. Gambliel, H.A., Burke, B.E., Cusack, B.J., Walsh, G.M., Zhang, Y.L., Mushlin, P.S., Olson, R.D. Biochem. Biophys. Res. Commun. (2002) [Pubmed]
WikiGenes - Universities